We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Arcalyst’s sBLA Review Shows Need for Attention to Target Population
Arcalyst’s sBLA Review Shows Need for Attention to Target Population
May 23, 2012
Safety and efficacy data for Regeneron’s Arcalyst do not support an indication to prevent gout flares, an FDA advisory panel voted unanimously.